PE20150721A1 - Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion - Google Patents
Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacionInfo
- Publication number
- PE20150721A1 PE20150721A1 PE2015000462A PE2015000462A PE20150721A1 PE 20150721 A1 PE20150721 A1 PE 20150721A1 PE 2015000462 A PE2015000462 A PE 2015000462A PE 2015000462 A PE2015000462 A PE 2015000462A PE 20150721 A1 PE20150721 A1 PE 20150721A1
- Authority
- PE
- Peru
- Prior art keywords
- gemigliptin
- metformin
- pharmaceutical composition
- preparation
- composition including
- Prior art date
Links
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 title abstract 4
- 229960002458 gemigliptin Drugs 0.000 title abstract 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 4
- 229960003105 metformin Drugs 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
LA INVENCION SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE GEMIGLIPTINA Y METFORMINA COMO COMPONENTES ACTIVOS, Y A UN METODO PARA SU PREPARACION. LA COMPOSICION FARMACEUTICA, QUE CONSISTE EN UNA PRIMERA CAPA QUE COMPRENDE METFORMINA Y UNA SEGUNDA CAPA QUE COMPRENDE GEMIGLIPTINA DE ACUERDO CON LA INVENCION, TIENE UN EFECTO SUPERIOR EN LA PREVENCION Y EL TRATAMIENTO DE LA DIABETES Y SUS COMPLICACIONES, Y REDUCE LOS EFECTOS PERJUDICIALES DE CADA COMPONENTE. ADEMAS, LA COMPOSICION COMPRENDE GEMIGLIPTINA Y METFORMINA EN FORMA SEPARADA, A FIN DE MANTENER LAS VELOCIDADES DE DISOLUCION INHERENTES DE AMBOS COMPONENTES Y MEJORAR EL CUMPLIMIENTO POR PARTE DEL PACIENTE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120111404 | 2012-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20150721A1 true PE20150721A1 (es) | 2015-05-23 |
Family
ID=50477605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000462A PE20150721A1 (es) | 2012-10-08 | 2013-10-07 | Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP2903602B1 (es) |
| KR (1) | KR101526553B1 (es) |
| CN (2) | CN104884051A (es) |
| AU (1) | AU2013330679B2 (es) |
| BR (1) | BR112015007360A8 (es) |
| CL (1) | CL2015000857A1 (es) |
| DO (1) | DOP2015000071A (es) |
| HK (1) | HK1211849A1 (es) |
| MX (1) | MX368184B (es) |
| MY (1) | MY174238A (es) |
| PE (1) | PE20150721A1 (es) |
| PH (1) | PH12015500653B1 (es) |
| RU (1) | RU2664422C2 (es) |
| SG (1) | SG11201502241XA (es) |
| TW (1) | TWI606848B (es) |
| UA (1) | UA114527C2 (es) |
| UY (1) | UY35065A (es) |
| WO (1) | WO2014058188A1 (es) |
| ZA (1) | ZA201501985B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102496851B1 (ko) | 2015-04-10 | 2023-02-08 | 제이더블유중외제약 주식회사 | 아나글립틴 또는 이의 약학적으로 허용 가능한 염 및 메트포르민 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물 및 그의 제조 방법 |
| PE20191502A1 (es) * | 2016-11-15 | 2019-10-22 | Lg Chemical Ltd | Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabetica |
| WO2020091406A1 (ko) * | 2018-10-31 | 2020-05-07 | 주식회사 엘지화학 | 제2형 당뇨병 치료용 약제학적 조성물 |
| KR102633770B1 (ko) | 2019-05-24 | 2024-02-02 | 주식회사 엘지화학 | 제2형 당뇨병 치료용 복합제제 |
| CN112641776A (zh) * | 2019-10-12 | 2021-04-13 | 江苏晶立信医药科技有限公司 | 一种以二甲双胍或其可药用盐和澳格列汀或其可药用盐为活性成分的药用组合物 |
| BR112023002559A2 (pt) * | 2020-08-14 | 2023-03-14 | Lg Chemical Ltd | Preparação de combinação para tratar diabetes tipo 2 |
| CN112546013B (zh) * | 2020-12-29 | 2022-06-10 | 平光制药股份有限公司 | 一种沙格列汀二甲双胍双层片及其制备工艺 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20035A3 (cs) * | 2000-07-06 | 2003-05-14 | Metabasis Therapeutics, Inc. | Kombinace FBPázových inhibitorů a antidiabetických činidel užitečná při léčení diabetes |
| WO2005060942A1 (en) * | 2003-12-19 | 2005-07-07 | Aurobindo Pharma Ltd | Extended release pharmaceutical composition of metformin |
| US20100323011A1 (en) * | 2008-03-04 | 2010-12-23 | Nazaneen Pourkavoos | Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor |
| US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
| PE20140960A1 (es) * | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| CA2776296C (en) * | 2009-10-02 | 2017-11-07 | Boehringer Ingelheim International Gmbh | Therapeutic uses of pharmaceutical compositions |
| EP2356985A1 (en) * | 2010-02-10 | 2011-08-17 | LEK Pharmaceuticals d.d. | Novel pharmaceutical compositions comprising a combination of metformin and sitagliptin |
| WO2012049566A1 (en) * | 2010-10-14 | 2012-04-19 | Japan Tobacco Inc. | Combination therapy for use in treating diabetes |
| CA2813671A1 (en) * | 2010-11-02 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
| WO2012090225A2 (en) * | 2010-12-29 | 2012-07-05 | Nutracryst Therapeutics Private Limited | Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent |
| AR085689A1 (es) * | 2011-03-07 | 2013-10-23 | Boehringer Ingelheim Int | Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2 |
-
2013
- 2013-10-04 TW TW102135966A patent/TWI606848B/zh active
- 2013-10-04 UY UY0001035065A patent/UY35065A/es active IP Right Grant
- 2013-10-07 WO PCT/KR2013/008932 patent/WO2014058188A1/en not_active Ceased
- 2013-10-07 UA UAA201504529A patent/UA114527C2/uk unknown
- 2013-10-07 KR KR1020130119059A patent/KR101526553B1/ko active Active
- 2013-10-07 EP EP13844898.0A patent/EP2903602B1/en not_active Not-in-force
- 2013-10-07 PE PE2015000462A patent/PE20150721A1/es active IP Right Grant
- 2013-10-07 RU RU2015117523A patent/RU2664422C2/ru active
- 2013-10-07 MY MYPI2015700907A patent/MY174238A/en unknown
- 2013-10-07 HK HK15112746.5A patent/HK1211849A1/xx unknown
- 2013-10-07 AU AU2013330679A patent/AU2013330679B2/en active Active
- 2013-10-07 MX MX2015004296A patent/MX368184B/es active IP Right Grant
- 2013-10-07 SG SG11201502241XA patent/SG11201502241XA/en unknown
- 2013-10-07 CN CN201380052265.XA patent/CN104884051A/zh active Pending
- 2013-10-07 CN CN201910676778.7A patent/CN110339176A/zh active Pending
- 2013-10-07 BR BR112015007360A patent/BR112015007360A8/pt not_active Application Discontinuation
-
2015
- 2015-03-23 ZA ZA2015/01985A patent/ZA201501985B/en unknown
- 2015-03-23 DO DO2015000071A patent/DOP2015000071A/es unknown
- 2015-03-24 PH PH12015500653A patent/PH12015500653B1/en unknown
- 2015-04-06 CL CL2015000857A patent/CL2015000857A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2903602A4 (en) | 2016-03-16 |
| SG11201502241XA (en) | 2015-04-29 |
| TWI606848B (zh) | 2017-12-01 |
| AU2013330679A8 (en) | 2015-04-16 |
| DOP2015000071A (es) | 2018-06-30 |
| KR20140045271A (ko) | 2014-04-16 |
| CN110339176A (zh) | 2019-10-18 |
| MY174238A (en) | 2020-04-01 |
| AU2013330679B2 (en) | 2016-10-06 |
| HK1211849A1 (en) | 2016-06-03 |
| PH12015500653A1 (en) | 2015-05-11 |
| BR112015007360A2 (pt) | 2017-07-04 |
| RU2664422C2 (ru) | 2018-08-17 |
| RU2015117523A (ru) | 2016-11-27 |
| EP2903602A1 (en) | 2015-08-12 |
| BR112015007360A8 (pt) | 2018-08-14 |
| PH12015500653B1 (en) | 2015-05-11 |
| MX368184B (es) | 2019-09-23 |
| CL2015000857A1 (es) | 2015-08-21 |
| AU2013330679A1 (en) | 2015-04-09 |
| KR101526553B1 (ko) | 2015-06-09 |
| CN104884051A (zh) | 2015-09-02 |
| MX2015004296A (es) | 2015-08-07 |
| TW201416095A (zh) | 2014-05-01 |
| UA114527C2 (uk) | 2017-06-26 |
| EP2903602B1 (en) | 2019-09-18 |
| WO2014058188A1 (en) | 2014-04-17 |
| ZA201501985B (en) | 2016-01-27 |
| UY35065A (es) | 2014-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19021223A (es) | Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo | |
| PE20150721A1 (es) | Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion | |
| MX393610B (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CL2013001982A1 (es) | Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad. | |
| MX2015009104A (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| CL2014002077A1 (es) | Composicion farmaceutica que comprende fumarato de dimetilo; metodo de preparacion; capsula que comprende microtabletas de fumarato de dimetilo; metodo para el tratamiento, profilaxis o mejora de la esclerosis multiple. | |
| CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
| MX383715B (es) | Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas. | |
| DOP2016000253A (es) | Nuevos compuestos | |
| NI201500135A (es) | Composición farmacéutica de hidrocloruro de s-ketamina | |
| MX2015010139A (es) | Composicion antiseptica oral para tratamiento de mucositis oral. | |
| MX2018003497A (es) | Formulaciones de aminoacidos de liberacion modificada administradas por via oral. | |
| MX2016008429A (es) | Derivado de piranocromenil fenol, y composicion farmaceutica para tratar un sindrome metabolico o enfermedad inflamatoria. | |
| CO2017006898A2 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| PE20151810A1 (es) | Composiciones farmaceuticas que comprenden everolimus | |
| MX2016013236A (es) | Formulacion inmunosupresora. | |
| CL2013002700A1 (es) | Cápsula suave ingerible que contiene inositol y excipientes, o inositol, excipientes y al menos un principio activo adicional, tal como ácido fólico, polifenoles de cocoa, genisteína, l-arginina, vitamina e, selenio, n-acetilcisteína y melatonina; útil para el tratamiento del ovario poliquístico, resistencia a la insulina y otros | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| CR20160235A (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| BR112015029894A2 (pt) | forma de dosagem farmacêutica sólida | |
| DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
| CO2018002428A2 (es) | Amida seleccionada de ácido gamma-hidroxiburico y usos de la misma en el tratamiento de abuso de alcohol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |